1. Scrip

Merck & Co. Buys Into Mestag's Fibroblast Approach To Treat Inflammation

 
• By Kevin Grogan

Deal Snapshot: The Cambridge, UK-based company could be in line for payments just shy of $2bn if its partnership with the US giant comes up trumps.

Susan Hill
Susan Hill • Source: Mestag

Who: Mestag/Merck & Co

What: The UK biotech has entered into a license and collaboration agreement with the US behemoth to identify targets for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas